The large cap biotech industry remains mired in a downtrend trend since posting a near-term top in the summer of 2015. Growth has clearly slowed and in some cases turned negative–we review the recent earnings reports of some of the largest companies.
By Alexander J. Poulos
Biogen: Still Waiting For a Catalyst
